US restarts ship­ments of two mAbs that don't work against Omi­cron as Mer­ck pills see wider dis­tri­b­u­tion

For any­one who’s been fol­low­ing how the US gov­ern­ment has been al­lo­cat­ing and ship­ping sup­plies of its Covid-19 treat­ments over the past year, the news has shift­ed so many times that it can be dif­fi­cult to keep track of what’s still be­ing shipped and where.

More change is com­ing this week too, as HHS has now de­cid­ed to re-start ship­ments of both Eli Lil­ly (bam­lanivimab plus ete­se­vimab) and Re­gen­eron (casiriv­imab plus imde­vimab) mon­o­clon­al an­ti­body prod­ucts af­ter a short pause be­cause nei­ther prod­uct works against the new vari­ant Omi­cron. Lil­ly’s com­bo al­so was halt­ed last June due to the pres­ence of oth­er vari­ants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER